Go offline with the Player FM app!
Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape
Manage episode 345141697 series 3256997
In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:
- How to sequence currently available therapies after relapse
- Challenges with using BCMA-targeted agents in clinical practice
- Experts’ thoughts on the potential approval of bispecific agents
Presenters include:
Paul G. Richardson, MD
RJ Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana Farber Cancer Institute
Boston, Massachusetts
Natalie S. Callander, MD
Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director
Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content for this program was supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; and Regeneron Pharmaceuticals, Inc.
Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3Fc7eMK
177 episodes
Manage episode 345141697 series 3256997
In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:
- How to sequence currently available therapies after relapse
- Challenges with using BCMA-targeted agents in clinical practice
- Experts’ thoughts on the potential approval of bispecific agents
Presenters include:
Paul G. Richardson, MD
RJ Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana Farber Cancer Institute
Boston, Massachusetts
Natalie S. Callander, MD
Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director
Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content for this program was supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; and Regeneron Pharmaceuticals, Inc.
Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3Fc7eMK
177 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.